Skip Navigation


JAC Advance Access originally published online on March 24, 2005
Journal of Antimicrobial Chemotherapy 2005 55(5):809-810; doi:10.1093/jac/dki096
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/5/809    most recent
dki096v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Correspondence

In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates

C. Betriu*, M. Gómez, I. Rodríguez-Avial, E. Culebras and J. J. Picazo

Department of Clinical Microbiology, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain

* Corresponding author. Tel: +34-913303486; Fax: +34-913303478; Email: cbetriu@efd.net

Keywords: glycylcyclines , antimicrobial susceptibility , respiratory infections

The first 10% of the full text of this article appears below.

Sir,

The increasing resistance in Haemophilus influenzae has complicated the choice of antibiotics for empirical treatment of community-acquired respiratory tract infection. Tigecycline, a glycylcycline, is a new semi-synthetic 9-t-butylglycylamido derivative of minocycline with potent in vitro activity against a wide variety of Gram-positive and Gram-negative organisms, including multidrug-resistant strains.1 Tigecycline overcomes the two . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Izdebski, E. Sadowy, J. Fiett, P. Grzesiowski, M. Gniadkowski, and W. Hryniewicz
Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1155 - 1163.
[Abstract] [Full Text] [PDF]